Although the paper did not breakdown the data by tumor grade, since the majority of patients had grade 3 tumors, DS-1001 (safusidenib) appears to be active for both enhancing and non-enhancing grade 2 and 3 IDH-mutant gliomas. This evidence concerns the gene IDH2 and neoplasm.